Pancreatic Cancer Research

ResearcherCapital Medical UniversityActive in the last 2 years

Dong Yan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2483-4029; OpenAlex author ID A5042265572. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
13
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 4

  1. Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. First author DOI 10.1038/s41416-025-03286-w↗
  2. The glycolytic enzyme PGK1 phosphorylates MORC2 to Confer radioresistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41419-025-08177-9↗
  3. Hexokinase 2 nonmetabolic function-mediated phosphorylation of IκBα enhances pancreatic ductal adenocarcinoma progression. Last author DOI 10.1111/cas.16204↗
  4. Clinically relevant circulating microRNA profiling studies in pancreatic cancer using meta-analysis. Co-author DOI 10.18632/oncotarget.15148↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yingying Tong · 2 shared papers, 2024–2025 · strength 0.43
  2. Li Wang · 2 shared papers, 2024–2025 · strength 0.43
  3. Jing Wang · 2 shared papers, 2024–2025 · strength 0.43
  4. yaoxian Xiang · 2 shared papers, 2024–2025 · strength 0.43
  5. Xinfang Hou · 1 shared paper, 2026 · strength 0.24
  6. Jianzhen Shan · 1 shared paper, 2026 · strength 0.24
  7. Noboru Yamamoto · 1 shared paper, 2026 · strength 0.24
  8. Vinod Ganju · 1 shared paper, 2026 · strength 0.24
  9. Rui‐Hua Xu · 1 shared paper, 2026 · strength 0.24
  10. Lijun Yang · 1 shared paper, 2025 · strength 0.22
  11. Zenglin Pei · 1 shared paper, 2017 · strength 0.06
  12. Jianqing Xu · 1 shared paper, 2017 · strength 0.06
  13. Jin Wang · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.